Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: nohalo who wrote (1158)	6/1/2000 10:23:00 PM
From: JMarcus	Read Replies (1) \| Respond to of 52153

>>Double blind trials are designed in such a way that the investigator (doctor or nurse) has no knowledge of which of their patients are getting the active drug. Strict criteria are established for these double blind trials.<< True, but if investigators (who know what the usual prognosis is when ineffective medicine is administered) see a much larger number than normal number of patients showing a very significant improvement, wouldn't they be tempted to infer (a) that the patients who are improving are probably the ones getting the active drug and (b) that the active drug must really work? The flip side would also be true: if the investigators see no big difference between the outcomes among their trial patients and the outcomes they are used to seeing when ineffective medicine is administered, the investigators would surely infer that the active drug isn't a miracle cure after all. Marc